Reuters logo
BRIEF-Abbvie submits NDA to U.S. FDA for investigational oral treatment Elagolix for management of endometriosis with associated pain
September 6, 2017 / 12:06 PM / 3 months ago

BRIEF-Abbvie submits NDA to U.S. FDA for investigational oral treatment Elagolix for management of endometriosis with associated pain

Sept 6 (Reuters) - Abbvie Inc:

* Abbvie submits new drug application to U.S. FDA for investigational oral treatment Elagolix for the management of endometriosis with associated pain

* Abbvie Inc - ‍submitted NDA to U.S. Food and drug administration for Elagolix​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below